Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on June 22, 2023, covering events that occurred on June 20, 2023. The filing addresses changes to the Company's Board of Directors and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and equity compensation agreements.
Material Changes
- Board Resignation: Stefan Galluppi resigned from the Board of Directors effective June 20, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices. Mr. Galluppi will continue to serve as the Company's Chief Innovation Officer.
- Board Appointment: William J. Febbo was appointed to the Board of Directors on June 20, 2023. Mr. Febbo is currently the CEO and a Director of OptimizeRx Corporation (Nasdaq: OPRX).
Compensation, Agreements, and Outlook
In connection with his appointment, Mr. Febbo entered into several agreements with the Company:
- Director Agreement (June 20, 2023):
- Granted 75,000 restricted shares of common stock (37,500 vest immediately; 37,500 vest on the two-year anniversary).
- Granted a stock option to purchase 37,500 shares of common stock (vesting on the two-year anniversary).
- Includes acceleration provisions for unvested shares in the event of removal without "Cause" or a "Change in Control."
- Consulting Services Agreement (May 30, 2023):
- Mr. Febbo provides investor relations and strategic business development services.
- Compensation consists of 375,000 restricted shares of common stock vesting in quarterly installments from August 30, 2023, through November 30, 2024.
- Unvested shares are forfeitable upon termination but accelerate upon a "Change in Control."
The filing does not provide specific financial guidance, risk factors, or management commentary regarding future business outlook beyond the details of these agreements.
Investor Verification Checklist
- Verify the total equity dilution impact of the 450,000 restricted shares and 37,500 stock options granted to Mr. Febbo.
- Review the full text of the Consulting Services Agreement (Exhibit 10.4) and Director Agreement (Exhibit 10.1) for specific termination clauses and vesting conditions.
- Confirm the continued role and compensation of Stefan Galluppi as Chief Innovation Officer following his Board resignation.
- Assess the strategic fit of Mr. Febbo's background in digital health and M&A with LifeMD's current business strategy.